Abstract:Introduction The recognition of the key role of angiogenesis for cancer growth has opened new frontiers in oncology1. In cancer therapy, the development of novel drugs aimed at blocking angiogenic processes has spurred the need for imaging biomarkers able to assess and predict the response to therapy. In response, targeted contrast agents have been developed providing selective enhancement in areas of active angiogenesis by binding to specific molecules over-expressed in angiogenic tumor vasculature. In the context of ultrasound molecular imaging (USMI), the first and currently only clinical-translatable targeted ultrasound contrast agent (tUCA) is obtained from conventional UCA by decoration of the microbubble shell with ligands targeting the vascular endothelial growth receptor factor 2 (VEGFR2), over-expressed in several solid tumors1. Assessment of the level of binding has been adopted as an indirect way of quantifying angiogenesis. Semi-quantitatively, this is done by looking at the late-enhancement (LE) several minutes after injection, often in conjunction with the application of a high-pressure US burst to derive the differential targeted enhancement (dTE), i.e., the difference in the acoustic signal before and after the application of the high-pressure burst1,2. For quantitative assessment, we recently proposed pharmacokinetic modeling of the binding kinetics of tUCA by the first-pass binding model (FPB), enabling quantification of angiogenesis by estimation of the microbubble binding rate (Kb)3. Here, we show the feasibility of the method for angiogenesis imaging in 11 rat models of prostate cancer, and for therapy monitoring of colorectal cancer in 17 mice undergoing anti-angiogenic treatment. Methods Time-intensity curves extracted at each pixel/voxel of USMI loops were fitted by the FPB model for estimation of the microbubble binding rate Kb. This was compared to semi-quantitative assessment by LE and dTE for: (i) angiogenesis imaging of prostate cancer by comparing parameter values in cancer and healthy regions of interest (ROIs) in 11 rats; (ii) anti-angiogenic therapy monitoring by comparing parameter values in responders, non-responders, and control mice at 5 time points during anti-angiogenic treatment. Results and Discussion Table I shows the differences in USMI parameters in healthy and tumor ROIs, obtained in 11 prostate-tumor bearing rats. Figure 1 shows the changes in USMI parameters during antiangiogenic treatment, obtained in 17 colorectal cancer-bearing mice. The results suggest the microbubble binding rate Kb to be a promising quantitative biomarker of angiogenesis, enabling the distinction between healthy and cancer tissue, and the early prediction of the response to anti-antiangiogenic therapy.

Monitoring of anti-angiogenic therapy by quantitative ultrasound molecular imaging

Quantitative Ultrasound Molecular Imaging for Antiangiogenic Therapy Monitoring

Monitoring Response to Anticancer Therapy by Targeting Microbubbles to Tumor Vasculature

Pharmacokinetic Modeling of Targeted Ultrasound Contrast Agents for Quantitative Assessment of Anti-Angiogenic Therapy: a Longitudinal Case-Control Study in Colon Cancer

Quantitative evaluation of tumor angiogenesis using ultrasound molecular imaging

3-D Ultrasound Localization Microscopy for Identifying Microvascular Morphology Features of Tumor Angiogenesis at a Resolution Beyond the Diffraction Limit of Conventional Ultrasound

Monitoring microvascular tortuosity and velocity distribution response of 4T1 tumor to the DOX-NDs treatment using super-resolution ultrasound imaging

Pharmacokinetic modeling of targeted microbubbles: applications in angiogenesis imaging and therapy monitoring

Characterization of Spatially Mapped Volumetric Molecular Ultrasound Signals for Predicting Response to Anti-Vascular Therapy

Ultrasound Super-Resolution Imaging Enables Multiparameter Analyses of Tumor Angiogenesis During Growth

Noninvasive Contrast-Free 3D Evaluation of Tumor Angiogenesis with Ultrasensitive Ultrasound Microvessel Imaging

Longitudinal Monitoring Of Tumor Antiangiogenic Therapy With Near-Infrared Fluorophore-Labeled Agents Targeted To Integrin Alpha(V)Beta(3) And Vascular Endothelial Growth Factor

Optical-resolution Photoacoustic Microscopy for Monitoring Vascular Normalization During Anti-Angiogenic Therapy

Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin α v β 3 and vascular endothelial growth factor

Monitoring Treatment Efficacy of Antiangiogenic Therapy Combined With Hypoxia-Activated Prodrugs Online Using Functional MRI

Intravital imaging and cavitation monitoring of antivascular ultrasound in tumor microvasculature

Current trends in the characterization and monitoring of vascular response to cancer therapy

Non-invasive Monitoring of Ultrasound-Stimulated Microbubble Radiation Enhancement Using Photoacoustic Imaging

Quantitatively monitoring the change of blood flow with contrast-enhanced ultrasound in the assessment of antiangiogenic efficacy in a mouse hepatoma model

3-D Longitudinal Imaging of Tumor Angiogenesis in Mice in Vivo Using Ultrafast Doppler Tomography

Molecular ultrasound imaging with vascular endothelial growth factor receptor 2-targeted microbubbles in a mouse liver cancer model